| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aurora Kinase A | 28 | 2024 | 209 | 2.860 |
Why?
|
| Carcinoma, Pancreatic Ductal | 15 | 2024 | 1828 | 1.880 |
Why?
|
| Pancreatic Neoplasms | 26 | 2024 | 5257 | 1.870 |
Why?
|
| MicroRNAs | 11 | 2021 | 2887 | 1.540 |
Why?
|
| Aurora Kinases | 34 | 2013 | 193 | 1.450 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2024 | 236 | 1.270 |
Why?
|
| Aurora Kinase C | 5 | 2016 | 11 | 1.260 |
Why?
|
| Cell Transformation, Neoplastic | 14 | 2015 | 2453 | 1.170 |
Why?
|
| CA-19-9 Antigen | 5 | 2023 | 155 | 1.050 |
Why?
|
| Biomarkers, Tumor | 21 | 2024 | 10708 | 0.990 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2024 | 26 | 0.930 |
Why?
|
| SOXC Transcription Factors | 1 | 2024 | 58 | 0.910 |
Why?
|
| Aurora Kinase B | 7 | 2020 | 67 | 0.910 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2022 | 442 | 0.840 |
Why?
|
| Chromosomal Instability | 4 | 2020 | 229 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2024 | 9042 | 0.810 |
Why?
|
| Aneuploidy | 9 | 2008 | 382 | 0.790 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 134 | 0.760 |
Why?
|
| Breast Neoplasms | 15 | 2024 | 16215 | 0.700 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2024 | 690 | 0.700 |
Why?
|
| Centrosome | 6 | 2023 | 106 | 0.670 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 1012 | 0.630 |
Why?
|
| Mitosis | 11 | 2023 | 681 | 0.630 |
Why?
|
| Neoplasms | 10 | 2017 | 15927 | 0.580 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2016 | 202 | 0.580 |
Why?
|
| Chromosomal Proteins, Non-Histone | 3 | 2016 | 376 | 0.560 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 1441 | 0.550 |
Why?
|
| Phosphonoacetic Acid | 1 | 2015 | 19 | 0.510 |
Why?
|
| Cyclin A | 1 | 2015 | 49 | 0.510 |
Why?
|
| Disease Progression | 5 | 2024 | 6867 | 0.510 |
Why?
|
| Cell Communication | 1 | 2017 | 512 | 0.490 |
Why?
|
| Aspartic Acid | 1 | 2015 | 136 | 0.490 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 1340 | 0.480 |
Why?
|
| Cyst Fluid | 1 | 2014 | 22 | 0.480 |
Why?
|
| HeLa Cells | 12 | 2016 | 1685 | 0.480 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2015 | 252 | 0.470 |
Why?
|
| Pancreatic Cyst | 1 | 2014 | 111 | 0.440 |
Why?
|
| CpG Islands | 1 | 2015 | 671 | 0.410 |
Why?
|
| Humans | 93 | 2024 | 270740 | 0.410 |
Why?
|
| Testis | 2 | 2015 | 620 | 0.410 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2012 | 30 | 0.400 |
Why?
|
| Phosphorylation | 13 | 2016 | 4942 | 0.390 |
Why?
|
| Chromosome Aberrations | 6 | 2010 | 2035 | 0.390 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2013 | 1903 | 0.380 |
Why?
|
| Kinetochores | 2 | 2008 | 28 | 0.380 |
Why?
|
| Gene Amplification | 10 | 2008 | 766 | 0.370 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 14849 | 0.370 |
Why?
|
| Cell Division | 5 | 2012 | 2657 | 0.360 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 1586 | 0.360 |
Why?
|
| Genes, p53 | 3 | 2005 | 1140 | 0.350 |
Why?
|
| Animals | 41 | 2024 | 61956 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 14 | 2012 | 5759 | 0.330 |
Why?
|
| Estrogen Receptor alpha | 2 | 2011 | 692 | 0.330 |
Why?
|
| Neoplasm Metastasis | 4 | 2017 | 5315 | 0.330 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 144 | 0.330 |
Why?
|
| Adenocarcinoma | 7 | 2016 | 7914 | 0.320 |
Why?
|
| Mice | 26 | 2024 | 35600 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2015 | 1347 | 0.320 |
Why?
|
| Nuclear Proteins | 3 | 2012 | 3438 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2011 | 3658 | 0.310 |
Why?
|
| G2 Phase | 6 | 2007 | 218 | 0.310 |
Why?
|
| Genomic Instability | 4 | 2013 | 521 | 0.300 |
Why?
|
| Apoptosis | 10 | 2015 | 7757 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 5408 | 0.290 |
Why?
|
| Microtubules | 1 | 2008 | 329 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 10400 | 0.280 |
Why?
|
| Protein Binding | 7 | 2020 | 3485 | 0.270 |
Why?
|
| Chromosomes, Human | 2 | 2004 | 288 | 0.270 |
Why?
|
| Cell Cycle | 10 | 2010 | 2137 | 0.270 |
Why?
|
| RNA, Messenger | 14 | 2014 | 6390 | 0.270 |
Why?
|
| Chromatin | 3 | 2008 | 1046 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 20 | 3 | 2004 | 64 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2016 | 5776 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 2359 | 0.250 |
Why?
|
| DNA Damage | 3 | 2012 | 1989 | 0.250 |
Why?
|
| Signal Transduction | 6 | 2024 | 12103 | 0.250 |
Why?
|
| DNA Methylation | 1 | 2015 | 2765 | 0.240 |
Why?
|
| ROC Curve | 3 | 2021 | 1248 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2016 | 4644 | 0.240 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2014 | 3597 | 0.240 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2024 | 37 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 4 | 2024 | 4048 | 0.230 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2024 | 80 | 0.230 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2024 | 87 | 0.230 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2024 | 157 | 0.220 |
Why?
|
| Transcription Factor AP-1 | 1 | 2024 | 249 | 0.220 |
Why?
|
| Extrachromosomal Inheritance | 2 | 1994 | 5 | 0.220 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2023 | 78 | 0.220 |
Why?
|
| Female | 41 | 2024 | 148940 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2008 | 2431 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3035 | 0.210 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 107 | 0.210 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2224 | 0.210 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 589 | 0.210 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2024 | 264 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 1199 | 0.200 |
Why?
|
| DNA, Neoplasm | 6 | 2011 | 1958 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2013 | 329 | 0.200 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 350 | 0.200 |
Why?
|
| Case-Control Studies | 8 | 2021 | 6224 | 0.200 |
Why?
|
| Carcinoma | 2 | 2011 | 2610 | 0.200 |
Why?
|
| Carcinoma in Situ | 3 | 2020 | 489 | 0.200 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 105 | 0.190 |
Why?
|
| RNA, Long Noncoding | 2 | 2020 | 617 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 5002 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 694 | 0.190 |
Why?
|
| Chalcone | 1 | 2020 | 3 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 4961 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 10 | 2010 | 2313 | 0.190 |
Why?
|
| Benzophenones | 1 | 2020 | 14 | 0.180 |
Why?
|
| Tubulin Modulators | 1 | 2020 | 65 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 606 | 0.180 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 97 | 0.180 |
Why?
|
| Datasets as Topic | 1 | 2021 | 178 | 0.180 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2353 | 0.180 |
Why?
|
| Feedback | 1 | 2001 | 225 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2018 | 1002 | 0.180 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 784 | 0.170 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2001 | 223 | 0.170 |
Why?
|
| Transfection | 7 | 2011 | 3117 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2015 | 2422 | 0.170 |
Why?
|
| Gene Expression Profiling | 5 | 2013 | 5149 | 0.170 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14617 | 0.170 |
Why?
|
| Amino Acid Sequence | 4 | 2016 | 4567 | 0.170 |
Why?
|
| Tenascin | 2 | 2017 | 51 | 0.170 |
Why?
|
| Molecular Sequence Data | 8 | 2003 | 6685 | 0.170 |
Why?
|
| BRCA2 Protein | 2 | 2013 | 380 | 0.160 |
Why?
|
| Fibroblasts | 2 | 2004 | 1654 | 0.160 |
Why?
|
| Pancreas | 2 | 2021 | 744 | 0.160 |
Why?
|
| Cytokinesis | 2 | 2016 | 57 | 0.160 |
Why?
|
| Tubulin | 4 | 2020 | 202 | 0.160 |
Why?
|
| Models, Biological | 4 | 2016 | 3194 | 0.160 |
Why?
|
| Blotting, Southern | 5 | 2003 | 453 | 0.160 |
Why?
|
| Heterochromatin | 3 | 1986 | 90 | 0.160 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 26 | 0.160 |
Why?
|
| Glucose | 1 | 2024 | 1218 | 0.160 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2018 | 72 | 0.150 |
Why?
|
| Neoplasm Proteins | 4 | 2016 | 3345 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2010 | 299 | 0.150 |
Why?
|
| Lipoproteins | 2 | 2017 | 229 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4958 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 2004 | 4130 | 0.150 |
Why?
|
| Chromosomes | 4 | 2003 | 325 | 0.150 |
Why?
|
| Spindle Apparatus | 3 | 2023 | 111 | 0.150 |
Why?
|
| Phenylalanine-tRNA Ligase | 1 | 1997 | 4 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 537 | 0.150 |
Why?
|
| Cell Proliferation | 8 | 2024 | 7238 | 0.140 |
Why?
|
| Ovarian Neoplasms | 3 | 2013 | 4795 | 0.140 |
Why?
|
| Blotting, Western | 7 | 2013 | 3584 | 0.140 |
Why?
|
| Gene Silencing | 3 | 2016 | 827 | 0.140 |
Why?
|
| Mouth Neoplasms | 2 | 2020 | 734 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 6 | 2008 | 3476 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 3216 | 0.140 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2016 | 159 | 0.140 |
Why?
|
| Phosphoserine | 1 | 2016 | 109 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 561 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 1557 | 0.130 |
Why?
|
| Chromosome Segregation | 1 | 2016 | 84 | 0.130 |
Why?
|
| Mice, Nude | 5 | 2015 | 4329 | 0.130 |
Why?
|
| Metabolome | 1 | 2019 | 355 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 1121 | 0.130 |
Why?
|
| Protein Stability | 1 | 2016 | 377 | 0.120 |
Why?
|
| Metabolomics | 1 | 2019 | 504 | 0.120 |
Why?
|
| Indoles | 1 | 2020 | 1028 | 0.120 |
Why?
|
| Exosomes | 1 | 2017 | 255 | 0.120 |
Why?
|
| Transcriptional Activation | 2 | 2011 | 1111 | 0.120 |
Why?
|
| Chromosome Mapping | 4 | 1997 | 1655 | 0.120 |
Why?
|
| Conserved Sequence | 1 | 2016 | 498 | 0.120 |
Why?
|
| Male | 24 | 2021 | 128315 | 0.120 |
Why?
|
| Protein Domains | 1 | 2016 | 322 | 0.120 |
Why?
|
| Tumor Protein p73 | 2 | 2012 | 114 | 0.120 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 30998 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 1017 | 0.120 |
Why?
|
| Cytokines | 1 | 2023 | 2825 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 5162 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 2617 | 0.120 |
Why?
|
| Epithelium | 1 | 2016 | 782 | 0.120 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 574 | 0.120 |
Why?
|
| Gene Expression | 5 | 2010 | 3640 | 0.110 |
Why?
|
| Carcinogenesis | 2 | 2020 | 1033 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2651 | 0.110 |
Why?
|
| Proteins | 2 | 2013 | 2043 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2003 | 1082 | 0.110 |
Why?
|
| Aged | 16 | 2021 | 73333 | 0.110 |
Why?
|
| Indazoles | 1 | 2015 | 310 | 0.110 |
Why?
|
| Receptors, Endothelin | 1 | 2013 | 25 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2009 | 2196 | 0.110 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 46 | 0.110 |
Why?
|
| Prognosis | 9 | 2014 | 22505 | 0.110 |
Why?
|
| Genes, Retinoblastoma | 1 | 1993 | 92 | 0.110 |
Why?
|
| DNA, Complementary | 3 | 2007 | 938 | 0.110 |
Why?
|
| Retinoblastoma Protein | 2 | 1998 | 339 | 0.110 |
Why?
|
| Middle Aged | 18 | 2021 | 90352 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1412 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 12033 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2008 | 525 | 0.110 |
Why?
|
| Base Sequence | 8 | 1997 | 5437 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 619 | 0.100 |
Why?
|
| Leukemia, Myeloid | 2 | 1997 | 993 | 0.100 |
Why?
|
| DNA, Circular | 1 | 1992 | 35 | 0.100 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 3339 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 436 | 0.100 |
Why?
|
| Genome Components | 1 | 2011 | 3 | 0.100 |
Why?
|
| Tobacco, Smokeless | 1 | 2011 | 29 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 14012 | 0.090 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 162 | 0.090 |
Why?
|
| Enzymes | 1 | 2011 | 71 | 0.090 |
Why?
|
| Leukoplakia, Oral | 1 | 2011 | 71 | 0.090 |
Why?
|
| Binding Sites | 4 | 2016 | 2255 | 0.090 |
Why?
|
| Glutathione Transferase | 3 | 2007 | 367 | 0.090 |
Why?
|
| HL-60 Cells | 2 | 2004 | 318 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1994 | 586 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 2175 | 0.090 |
Why?
|
| Serine | 3 | 2007 | 391 | 0.090 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2010 | 15 | 0.090 |
Why?
|
| Enzyme Activators | 1 | 2010 | 21 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1994 | 441 | 0.090 |
Why?
|
| Homeopathy | 1 | 2010 | 7 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 231 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 680 | 0.090 |
Why?
|
| Drug Resistance | 5 | 1998 | 610 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 894 | 0.090 |
Why?
|
| Precipitin Tests | 2 | 2007 | 350 | 0.090 |
Why?
|
| Oxadiazoles | 1 | 2010 | 60 | 0.090 |
Why?
|
| Leupeptins | 1 | 2009 | 71 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1823 | 0.080 |
Why?
|
| Chromosome Disorders | 2 | 1995 | 423 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2009 | 593 | 0.080 |
Why?
|
| Protein Kinases | 2 | 2004 | 902 | 0.080 |
Why?
|
| Anaphase | 1 | 2009 | 54 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2010 | 101 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2010 | 167 | 0.080 |
Why?
|
| Histones | 4 | 2008 | 1513 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 324 | 0.080 |
Why?
|
| Telomere | 3 | 2010 | 550 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 637 | 0.080 |
Why?
|
| Immunohistochemistry | 7 | 2013 | 7655 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 804 | 0.080 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 316 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 506 | 0.080 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 235 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 1472 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 189 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1109 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2008 | 199 | 0.070 |
Why?
|
| Enzyme Stability | 1 | 2007 | 110 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2008 | 1810 | 0.070 |
Why?
|
| Cell Line | 9 | 2018 | 5338 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 622 | 0.070 |
Why?
|
| Adult | 13 | 2021 | 82040 | 0.070 |
Why?
|
| Cyclin D1 | 1 | 2010 | 589 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 690 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2009 | 2101 | 0.070 |
Why?
|
| Skin | 1 | 2012 | 1271 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 1076 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2016 | 823 | 0.070 |
Why?
|
| CCAAT-Binding Factor | 1 | 2006 | 34 | 0.070 |
Why?
|
| Cyclin B | 1 | 2006 | 69 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2007 | 581 | 0.070 |
Why?
|
| Piperazines | 1 | 2015 | 2145 | 0.070 |
Why?
|
| Gene Library | 1 | 2007 | 353 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1995 | 2635 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4821 | 0.070 |
Why?
|
| Muridae | 1 | 1986 | 23 | 0.070 |
Why?
|
| Xenopus Proteins | 2 | 2004 | 193 | 0.070 |
Why?
|
| Mutation | 8 | 2013 | 15912 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 693 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 530 | 0.060 |
Why?
|
| Phenotype | 4 | 2018 | 6509 | 0.060 |
Why?
|
| Pancreatitis, Chronic | 2 | 2017 | 130 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 6 | 1987 | 632 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 1985 | 40 | 0.060 |
Why?
|
| Cricetinae | 6 | 1999 | 769 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2007 | 1857 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 1435 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 1386 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2156 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3707 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 1998 | 413 | 0.060 |
Why?
|
| Point Mutation | 2 | 2000 | 788 | 0.060 |
Why?
|
| Centromere | 1 | 2004 | 139 | 0.060 |
Why?
|
| Young Adult | 2 | 2021 | 22251 | 0.060 |
Why?
|
| Hexokinase | 1 | 2024 | 36 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 547 | 0.060 |
Why?
|
| Cloning, Molecular | 3 | 1997 | 1430 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 2003 | 726 | 0.060 |
Why?
|
| Karyotyping | 5 | 1992 | 1063 | 0.050 |
Why?
|
| ras-GRF1 | 1 | 2003 | 6 | 0.050 |
Why?
|
| DNA | 4 | 1999 | 3050 | 0.050 |
Why?
|
| Mitochondria | 1 | 2010 | 1297 | 0.050 |
Why?
|
| Genotype | 4 | 2016 | 4252 | 0.050 |
Why?
|
| Pregnancy | 1 | 2016 | 8130 | 0.050 |
Why?
|
| Cyclin D2 | 1 | 2023 | 40 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2012 | 4116 | 0.050 |
Why?
|
| Germinoma | 1 | 2003 | 82 | 0.050 |
Why?
|
| Cell Movement | 1 | 2010 | 2472 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 264 | 0.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2007 | 481 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 300 | 0.050 |
Why?
|
| Flow Cytometry | 5 | 2010 | 3045 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7895 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 2170 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 840 | 0.050 |
Why?
|
| Breast | 1 | 2009 | 1369 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 1642 | 0.050 |
Why?
|
| Sex Chromosomes | 1 | 1982 | 44 | 0.050 |
Why?
|
| Tripartite Motif Proteins | 2 | 2013 | 50 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1998 | 275 | 0.050 |
Why?
|
| Protein Phosphatase 1 | 1 | 2001 | 79 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 999 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 5593 | 0.050 |
Why?
|
| Rats | 1 | 2010 | 6441 | 0.050 |
Why?
|
| Glycolysis | 2 | 2019 | 530 | 0.050 |
Why?
|
| Colchicine | 1 | 2020 | 68 | 0.050 |
Why?
|
| DNA Probes | 3 | 1999 | 247 | 0.050 |
Why?
|
| Azoxymethane | 1 | 2020 | 44 | 0.050 |
Why?
|
| X Chromosome | 1 | 1982 | 402 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 528 | 0.050 |
Why?
|
| DNA Replication | 2 | 1982 | 770 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2007 | 950 | 0.040 |
Why?
|
| Dextrans | 1 | 2020 | 98 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2023 | 1875 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1189 | 0.040 |
Why?
|
| DNA, Satellite | 1 | 1980 | 44 | 0.040 |
Why?
|
| Keratinocytes | 2 | 2012 | 244 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2023 | 440 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 885 | 0.040 |
Why?
|
| India | 2 | 2011 | 318 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 199 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 163 | 0.040 |
Why?
|
| DNA Primers | 2 | 2008 | 1496 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 305 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 239 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 526 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 4147 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2020 | 363 | 0.040 |
Why?
|
| Hybrid Cells | 2 | 1997 | 148 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 3028 | 0.040 |
Why?
|
| Testicular Neoplasms | 1 | 2003 | 560 | 0.040 |
Why?
|
| Age Factors | 3 | 2017 | 5457 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 2357 | 0.040 |
Why?
|
| Chromosome Fragility | 1 | 1998 | 33 | 0.040 |
Why?
|
| Picolinic Acids | 1 | 2018 | 16 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 183 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 2573 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2004 | 2115 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4223 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 1998 | 276 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 132 | 0.040 |
Why?
|
| Benzothiazoles | 1 | 2018 | 103 | 0.040 |
Why?
|
| Thermus thermophilus | 1 | 1997 | 13 | 0.040 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1997 | 53 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 471 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 310 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1997 | 88 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 1246 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 332 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2010 | 6764 | 0.040 |
Why?
|
| Vimentin | 1 | 2018 | 252 | 0.040 |
Why?
|
| Rodentia | 1 | 1997 | 71 | 0.040 |
Why?
|
| Yeasts | 1 | 1997 | 76 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1997 | 330 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 375 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 396 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 2828 | 0.030 |
Why?
|
| Polyploidy | 2 | 2012 | 76 | 0.030 |
Why?
|
| Heterografts | 1 | 2019 | 738 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1997 | 336 | 0.030 |
Why?
|
| Haplotypes | 2 | 2011 | 910 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 659 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 1998 | 623 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 413 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2013 | 875 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2486 | 0.030 |
Why?
|
| Time Factors | 3 | 2008 | 13006 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2471 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 768 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1997 | 250 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 247 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2007 | 1275 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 729 | 0.030 |
Why?
|
| Kinetics | 2 | 2002 | 2220 | 0.030 |
Why?
|
| Age of Onset | 2 | 2008 | 853 | 0.030 |
Why?
|
| Mammals | 1 | 1997 | 369 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 192 | 0.030 |
Why?
|
| Cell Separation | 2 | 2010 | 609 | 0.030 |
Why?
|
| Risk Factors | 4 | 2016 | 17888 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 7265 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 876 | 0.030 |
Why?
|
| Cholestasis | 1 | 2017 | 207 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 657 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 2328 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 384 | 0.030 |
Why?
|
| Alleles | 3 | 2010 | 2600 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 3917 | 0.030 |
Why?
|
| Micromanipulation | 1 | 1994 | 10 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 1126 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 9470 | 0.030 |
Why?
|
| Genetic Variation | 3 | 2010 | 2166 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 809 | 0.030 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 4963 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 120 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2013 | 123 | 0.030 |
Why?
|
| Keratins, Hair-Specific | 1 | 2012 | 4 | 0.030 |
Why?
|
| Keratin-1 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2012 | 24 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 4895 | 0.030 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2013 | 91 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 290 | 0.030 |
Why?
|
| Cell Death | 2 | 2009 | 685 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 156 | 0.030 |
Why?
|
| Cricetulus | 3 | 1987 | 214 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2015 | 437 | 0.030 |
Why?
|
| Genes, myc | 1 | 1994 | 371 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1995 | 668 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 2493 | 0.030 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1992 | 50 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 460 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2004 | 631 | 0.020 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1992 | 71 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 354 | 0.020 |
Why?
|
| Drosophila | 1 | 1997 | 909 | 0.020 |
Why?
|
| Chromosome Banding | 2 | 1994 | 280 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2197 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 3298 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 1553 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1994 | 805 | 0.020 |
Why?
|
| Smoking | 2 | 2011 | 2555 | 0.020 |
Why?
|
| Plasmids | 2 | 2004 | 936 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2013 | 579 | 0.020 |
Why?
|
| Metaphase | 2 | 1999 | 124 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 503 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1994 | 813 | 0.020 |
Why?
|
| Phytolacca | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thuja | 1 | 2010 | 3 | 0.020 |
Why?
|
| Conium | 1 | 2010 | 3 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2010 | 143 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 444 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 494 | 0.020 |
Why?
|
| Micronucleus Tests | 1 | 1989 | 19 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2011 | 205 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 1291 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2006 | 909 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 1099 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2006 | 1497 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 374 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2009 | 128 | 0.020 |
Why?
|
| Papilloma | 1 | 2009 | 86 | 0.020 |
Why?
|
| Ethanol | 1 | 2011 | 272 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2008 | 1712 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1461 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 16689 | 0.020 |
Why?
|
| Deoxyribonuclease I | 2 | 1987 | 84 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 7100 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2010 | 262 | 0.020 |
Why?
|
| Vinblastine | 1 | 1989 | 462 | 0.020 |
Why?
|
| Ovary | 3 | 1987 | 688 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 1024 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 590 | 0.020 |
Why?
|
| G1 Phase | 1 | 2009 | 305 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 2454 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 896 | 0.020 |
Why?
|
| Chickens | 2 | 1987 | 783 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2009 | 319 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 679 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 1525 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 515 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2010 | 39890 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 1474 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2006 | 60 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 1312 | 0.020 |
Why?
|
| TATA-Box Binding Protein | 1 | 2006 | 38 | 0.020 |
Why?
|
| Ploidies | 1 | 2007 | 250 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 611 | 0.020 |
Why?
|
| Tetracycline | 1 | 2006 | 106 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 427 | 0.020 |
Why?
|
| Cell Survival | 2 | 2010 | 3063 | 0.020 |
Why?
|
| Genes | 1 | 1987 | 606 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2007 | 248 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 313 | 0.020 |
Why?
|
| Stem Cells | 1 | 2012 | 1216 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 2835 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2007 | 293 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2002 | 648 | 0.020 |
Why?
|
| Doxorubicin | 2 | 1989 | 3145 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2007 | 354 | 0.020 |
Why?
|
| Bortezomib | 1 | 2007 | 549 | 0.020 |
Why?
|
| Leukemia Virus, Murine | 1 | 1984 | 20 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 5694 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 2311 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 10265 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 706 | 0.010 |
Why?
|
| Cystectomy | 1 | 2008 | 635 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1986 | 290 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1985 | 223 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 143 | 0.010 |
Why?
|
| Pyrazines | 1 | 2007 | 510 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 13414 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 170 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1581 | 0.010 |
Why?
|
| Leydig Cell Tumor | 1 | 2003 | 9 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2090 | 0.010 |
Why?
|
| Seminiferous Tubules | 1 | 2003 | 35 | 0.010 |
Why?
|
| Carcinoma, Embryonal | 1 | 2003 | 31 | 0.010 |
Why?
|
| DNA Repair | 1 | 2011 | 1909 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 190 | 0.010 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2003 | 50 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 2271 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2008 | 1389 | 0.010 |
Why?
|
| Leukemia | 1 | 1992 | 1719 | 0.010 |
Why?
|
| Risk | 1 | 2007 | 1939 | 0.010 |
Why?
|
| Seminoma | 1 | 2003 | 86 | 0.010 |
Why?
|
| Atrophy | 1 | 2003 | 271 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 2351 | 0.010 |
Why?
|
| Protamine Kinase | 1 | 2002 | 19 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 895 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1050 | 0.010 |
Why?
|
| Catalysis | 1 | 2002 | 245 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2002 | 131 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 384 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5056 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1984 | 730 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1101 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6256 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2003 | 268 | 0.010 |
Why?
|
| Cisplatin | 1 | 2008 | 2497 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2002 | 721 | 0.010 |
Why?
|
| Teratoma | 1 | 2003 | 248 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 4000 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 1367 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2002 | 659 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2007 | 1402 | 0.010 |
Why?
|
| Interphase | 1 | 1999 | 156 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1379 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 5101 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 4831 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2013 | 5438 | 0.010 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 1999 | 32 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 206 | 0.010 |
Why?
|
| Chromosome Fragile Sites | 1 | 1998 | 38 | 0.010 |
Why?
|
| Species Specificity | 1 | 1980 | 794 | 0.010 |
Why?
|
| CHO Cells | 1 | 1999 | 320 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2004 | 1049 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 1553 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 9039 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 929 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12541 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 5231 | 0.010 |
Why?
|
| Adolescent | 2 | 2007 | 32767 | 0.010 |
Why?
|
| Vincristine | 2 | 1986 | 1583 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1992 | 68 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1992 | 197 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1994 | 1075 | 0.010 |
Why?
|
| Heterozygote | 1 | 1994 | 1056 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1992 | 425 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8699 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 1697 | 0.010 |
Why?
|
| Nucleotide Mapping | 1 | 1987 | 29 | 0.000 |
Why?
|
| Infant | 1 | 2003 | 13999 | 0.000 |
Why?
|
| Immunophenotyping | 1 | 1992 | 1726 | 0.000 |
Why?
|
| Demecolcine | 1 | 1986 | 20 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1984 | 161 | 0.000 |
Why?
|
| Methylation | 1 | 1984 | 625 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1984 | 1054 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1992 | 7381 | 0.000 |
Why?
|